Medium-term outcomes and prognostic factors after transcatheter paravalvular leak closure: an international prospective multicentre registry

Grégoire Albenque¹, MD; Grzegorz Smolka², MD, PhD; David Blanchard¹, MD; Martin Kloëckner¹, MD; Eric Brochet³, MD; Frederic Bouisset⁴, MD, PhD; Guillaume Leurent⁵, MD, PhD; Jean-Benoît Thambo⁶, MD, PhD; Nicolas Combes⁷, MD; Nicolas Dumonteil⁷, MD; Fabrice Bauer⁸, MD, PhD; Mohammed Nejjari⁹, MD; Rémy Pillière¹⁰, MD; Claire Dauphin¹¹, MD; Guillaume Bonnet¹², MD; Vlad Ciobotaru¹³, MD; Régis Kételers¹⁴, MD; Romain Gallet¹⁵, MD, PhD; Nadjib Hammoudi¹⁶, MD; Lionel Mangin¹⁷, MD; Hélène Bouvaist¹⁸, MD; Christian Spaulding¹⁹, MD, PhD; Adel Aminian²⁰, MD; Teoman Kilic²¹, MD; Batric Popovic²², MD; Sébastien Armero²³, MD; Didier Champagnac²⁴, MD; Benoît Gérardin¹, MD; Sebastien Hascoet¹, MD, PhD, FESC

Abstract

Background: Medium- and long-term outcomes after transcatheter paravalvular leak (PVL) closure remain poorly documented, with limited prospective data on predictors of morbidity and mortality.

Aims: This study aimed to assess medium-term outcomes and identify key predictive factors of mortality or surgical reintervention at 2 years after transcatheter PVL closure.

Methods: The prospective Fermeture de Fuite ParaProthétique (FFPP) Registry included consecutive symptomatic patients undergoing transcatheter PVL closure across 24 European centres between 2017 and 2019. Predictive factors for mortality and surgical reintervention were analysed over a 2-year follow-up.

Results: A total of 213 symptomatic patients underwent 237 procedures. The mean age was 68±11 years, with a median European System for Cardiac Operative Risk Evaluation (EuroSCORE) II of 6 (interquartile range [IQR] 4-10). PVL involved the mitral valve in 64.6% of cases and mechanical prostheses in 53.3%. Heart failure and haemolytic anaemia were present in 89.5% and 49.8% of patients, respectively. The transapical approach was used in 6.8% of cases. Technical success was achieved in 87.3% of procedures, and clinical success at 1 month was achieved in 70.5% of patients. The median follow-up was 24.4 months (IQR 23.2-26.4). The survival rate at 2 years without the need for surgical reintervention was 66.1% (95% confidence interval [CI]: 60.1-72.7). Multivariate analysis identified mitral PVL, mechanical valves, and haemolytic anaemia as independent risk factors for adverse outcomes during follow-up. The absence of clinical success at 1 month was the strongest predictor of adverse outcomes (hazard ratio 5.00, 95% CI: 2.70-9.09; p=0.001).

Conclusions: Transcatheter PVL closure offers a durable therapeutic option for high-risk patients when early clinical success is achieved. Mitral valve involvement, mechanical prostheses, and haemolytic anaemia remain key predictors of poor outcomes over a 2-year follow-up.

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com